Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F22%3A00126253" target="_blank" >RIV/00216224:14110/22:00126253 - isvavai.cz</a>

Result on the web

<a href="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01267-7" target="_blank" >https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01267-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13045-022-01267-7" target="_blank" >10.1186/s13045-022-01267-7</a>

Result language

angličtina

Original language name

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Original language description

Background Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed. Methods We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. Results AML patients with EM presented with significantly higher counts of white blood cells (p &lt; 0.0001), peripheral blood blasts (p &lt; 0.0001), bone marrow blasts (p = 0.019), and LDH (p &lt; 0.0001). Regarding molecular genetics, EM AML was associated with mutations of NPM1 (OR: 1.66, p &lt; 0.001), FLT3-ITD (OR: 1.72, p &lt; 0.001) and PTPN11 (OR: 2.46, p &lt; 0.001). With regard to clinical outcomes, EM AML patients were less likely to achieve complete remissions (OR: 0.62, p = 0.004), and had a higher early death rate (OR: 2.23, p = 0.003). Multivariable analysis revealed EM as an independent risk factor for reduced overall survival (hazard ratio [HR]: 1.43, p &lt; 0.001), however, for patients who received allogeneic hematopoietic cell transplantation (HCT) survival did not differ. For patients bearing EM AML, multivariable analysis unveiled mutated TP53 and IKZF1 as independent risk factors for reduced event-free (HR: 4.45, p &lt; 0.001, and HR: 2.05, p = 0.044, respectively) and overall survival (HR: 2.48, p = 0.026, and HR: 2.63, p = 0.008, respectively). Conclusion Our analysis represents one of the largest cohorts of EM AML and establishes key molecular markers linked to EM, providing new evidence that EM is associated with adverse risk in AML and may warrant allogeneic HCT in eligible patients with EM.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

JOURNAL OF HEMATOLOGY & ONCOLOGY

ISSN

1756-8722

e-ISSN

1756-8722

Volume of the periodical

15

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

1-13

UT code for WoS article

000795132900001

EID of the result in the Scopus database

2-s2.0-85130011025